Teva Pharmaceuticals Inc. finds itself at the center of a high-stakes legal battle as Jazz Pharmaceuticals Inc. has filed a lawsuit accusing Teva of infringing on its patent for the narcolepsy drug Xywav. The complaint, lodged Tuesday in a New Jersey federal court, alleges that Teva’s actions violate the intellectual property rights of Jazz Pharmaceuticals.
Teva Narcolepsy Drug Suit : Patent Dispute Heats Up
Xywav, an oral solution containing calcium, magnesium, potassium, and sodium oxybates, is used to manage narcolepsy symptoms such as cataplexy and excessive daytime sleepiness. Jazz Pharmaceuticals, headquartered in Dublin, Ireland, was granted a patent for Xywav by the U.S. Patent and Trademark Office on May 21, 2024. This patent, identified as U.S. Patent No. 11,986,446, is the crux of the legal dispute.
According to the complaint, Teva, based in Parsippany, New Jersey, has submitted an abbreviated new drug application to the U.S. Food and Drug Administration (FDA). This application seeks approval to produce, import, and sell a generic version of Xywav before the patent’s expiration.
Allegations and Legal Demands
Jazz Pharmaceuticals contends that Teva’s actions could lead to substantial and irreparable harm if not halted. The company claims that Teva’s proposed generic product infringes on its patent rights and seeks judicial intervention to prevent this.
